|Day's Range||25.70 - 26.01|
|52 Week Range||19.96 - 26.17|
|PE Ratio (TTM)||39.54|
|Dividend & Yield||0.78 (3.04%)|
|1y Target Est||N/A|
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.
CLEVELAND, May 24, 2017 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – is pleased to announce its ...
SAN FRANCISCO, May 22, 2017 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research collaboration to explore the combination of Nektar's lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from Takeda's cancer portfolio. The two companies will explore the anti-cancer activity of NKTR-214 with five different targeted mechanisms in preclinical tumor models of lymphoma, melanoma and colorectal cancer. "We look forward to collaborating with Takeda to explore a range of combination therapy approaches in models of both liquid and solid tumors," said Jonathan Zalevsky, PhD, Senior Vice President of Biology and Preclinical Development.